Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL Inc. (GRAL) is a leader in developing blood-based multi-cancer early detection solutions, most notably through its Galleri® test. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of cancer diagnostics.
Access timely announcements about peer-reviewed study results, partnership developments with leading research institutions, and progress in commercializing early detection technologies. Our curated news collection helps stakeholders track GRAIL’s innovations in methylation-based screening and machine learning applications.
Key updates include coverage of clinical validation studies, FDA regulatory communications, and collaborations with healthcare networks. All content is sourced from official releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to GRAIL’s latest developments in precision oncology. Check back regularly for insights into how the company is advancing its mission to detect cancer at its most treatable stages.
GRAIL (NASDAQ: GRAL) announced it will present new data for its Galleri® multi-cancer early detection (MCED) test at two major conferences. The company will showcase results from the PATHFINDER 2 study, the largest MCED interventional study in the U.S., at the ESMO Congress 2025 in Berlin. The study's top-line results demonstrated that adding Galleri to standard screening led to significantly improved cancer detection and higher positive predictive value compared to the first PATHFINDER study.
Additionally, GRAIL will present data from the SYMPLIFY study focusing on symptomatic participants and the REFLECTION study examining real-world experience in veterans at the Early Detection of Cancer Conference (EDCC) 2025 in Portland. The results will be part of GRAIL's FDA Premarket Approval Application for Galleri.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. The company's management will deliver their presentation on Wednesday, September 24, 2025, at 8:00 a.m. ET.
Investors and interested parties can access both the live webcast and replay through GRAIL's investor relations website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 27 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 47,150 shares of GRAIL's common stock.
The RSUs were granted under GRAIL's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans approximately four years, with 25% vesting on August 31, 2026, and the remaining portions vesting annually thereafter, contingent on continued employment.
GRAIL (NASDAQ:GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver their presentation on Tuesday, September 9 at 1:50 p.m. ET.
Investors can access both the live presentation and replay through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL) reported its Q2 2025 financial results, showing significant growth in its cancer detection business. Total revenue increased 11% year-over-year to $35.5 million, with U.S. Galleri revenue growing 21% to $34.2 million. The company sold over 45,000 Galleri tests in Q2, representing 29% growth year-over-year.
The company reported a net loss of $114.0 million, which includes a $28.0 million impairment of Illumina acquisition-related intangibles. GRAIL's PATHFINDER 2 study showed promising results, with improved cancer detection rates and higher positive predictive value compared to the first PATHFINDER study. The company maintained strong liquidity with $606.1 million in cash and equivalents as of June 30, 2025.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Wednesday, August 13 at 8:30 a.m. ET in Boston.
Investors can access both live and replay webcasts through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, will release its Q2 2025 financial results on Tuesday, August 12, 2025 after market close. Management will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results and business progress.
Interested parties can access the live webcast through GRAIL's investor relations website at investors.grail.com. Participants are advised to register at least ten minutes before the call's scheduled start time through the provided registration link.
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. The company's management will deliver a presentation on Tuesday, June 4 at 11:40 a.m. ET in New York. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
